Guide · 3 min read

Structured medication reviews: what PCNs must do in 2026/27

Six priority groups, three things every review should cover and one code to record it. Here's what the Network Contract DES asks of your PCN.

Checked against the sources listed at the end on .

The short answer

A structured medication review (SMR) is a full review of every medicine a patient takes, done with the patient as a shared decision. Under the Network Contract Directed Enhanced Service (DES), every primary care network (PCN) has to identify the patients who would benefit most, offer them an SMR and take wider steps to improve how medicines are used.

NHS England's guidance for 2026/27 names six groups to prioritise, including care home residents, people on 10 or more medicines and people on medicines linked to dependence. It asks each PCN to build a caseload so that the people in greatest need are seen first.

This guide sets out who to prioritise, what a review should cover, how to record it and where a pharmacy team fits.

Who to prioritise

PCNs should use appropriate tools to find the patients most at risk. The 2026/27 guidance lists:

  • people in care homes
  • people with learning disabilities
  • people with complex polypharmacy, especially those on 10 or more medicines
  • people on medicines commonly linked to errors and harm
  • people with severe frailty who are isolated or housebound, or who have recently been admitted to hospital or had a fall
  • people taking one or more medicines linked to dependence or withdrawal: antidepressants, opioids, gabapentinoids, benzodiazepines or Z-drugs

The guidance also asks PCNs to watch for groups at greater risk of health inequalities, such as Core20PLUS5 populations and people with learning disabilities. Simplifying a complicated regimen can make it safer.

What a review should cover

Clinicians should run each review on the principles of shared decision-making and personalisation. That means checking the patient understands why they're there, taking account of their health literacy and wider needs, and giving advice or referring them on where it helps. Referrals can include community pharmacy services such as the New Medicine Service.

The guidance asks clinicians to look at three things:

  • Safety: the balance of benefit and risk, side effects, and risks from other conditions or interactions.
  • Effectiveness: what each medicine is for, whether it's still needed, whether it's working and whether the patient wants to keep taking it.
  • Alternatives: whether the patient knows enough about other options, including social prescribing.

NHS England points to NICE guideline NG5 on medicines optimisation, the Royal Pharmaceutical Society's polypharmacy guidance and the National Overprescribing Review as the guidance to work from.

Invitations, follow-up and recording

The invitation, spoken or written, should explain what the review is: a conversation to go through all of the patient's medicines and check they're working well for them.

Follow-up appointments should be arranged where they're needed to make sure changes are safe and working. The clinician agrees how many with the patient, and another professional can do them. Every review and follow-up should be coded with the SNOMED CT code 1239511000000100 (structured medication review).

Wider medicines optimisation

SMRs sit inside a wider duty. The DES asks each PCN to set out how it will improve medicines optimisation and then do it, including cutting polypharmacy, prescribing harm and over-prescribing. The guidance suggests:

  • using NHS England's medicines optimisation opportunities dashboard on ePACT2, alongside your ICB's priorities
  • supporting national programmes such as Net Zero and STOMP (stopping the over-medication of people with a learning disability, autism or both)
  • using the NHS Business Services Authority's polypharmacy, opioid and antimicrobial comparators, and open tools such as OpenPrescribing
  • supporting national goals on antimicrobial resistance

Where your pharmacy team fits

SMRs are long, careful appointments, which is why many PCNs give them to their clinical pharmacists. A clinical pharmacist who is an independent prescriber can make the changes in the same consultation. A pharmacy technician can run the searches, send the invitations and handle the follow-up tasks, so pharmacist time goes on the reviews.

Clinical pharmacists and pharmacy technicians are both Additional Roles Reimbursement Scheme (ARRS) roles, so a PCN can fund them from its ARRS sum. Our ARRS 2026/27 guide explains how.

If your PCN doesn't have the capacity, our remote clinical pharmacists work through each cohort inside your clinical system, and every review shows up in your monthly report. Book a call with our clinical director.

Questions people ask

Is a structured medication review the same as a medication review?

No. A routine medication review can be a quick check of a repeat. An SMR goes through every medicine with the patient, looks at safety, effectiveness and alternatives, and is coded separately so it counts for the DES.

Do antidepressants count as a priority group?

Yes. Medicines linked to dependence or withdrawal, including antidepressants, opioids, gabapentinoids, benzodiazepines and Z-drugs, are one of the six priority groups in the 2026/27 guidance.

What code should we use?

NHS England's guidance asks for SNOMED CT code 1239511000000100 for each structured medication review and each follow-up.

Sources

  1. Network Contract DES 2026/27, Part A guidance: clinical and support services, section 8 (NHS England)
  2. Network Contract DES: contract specification 2026/27 (NHS England)
  3. Medicines optimisation, NICE guideline NG5

More guides

All guides